Table 3.
Clinical application of immunotherapy combined with radiotherapy in advanced melanoma.
| Researchers | Immunotherapy | Radiotherapy | Clinical results |
|---|---|---|---|
| Maity et al. (94) | 3 mg/kg ipilimumab | HFRT | Median PFS:3.6 months; Median OS:10.7 months |
| Boutros et al. (95) | 10 mg/kg ipilimumab | HFRT | Median PFS: 4.8 months; Median OS:10.8 months |
| Sundahl et al. (96) | Nivolumab | SBRT | Overall response rate: 45% |
| Curti et al. (97) | 600000 IU/kg Interleukin-2 | SBRT | ORR: 54%; DCR: 75% |
| Minor et al. (98) | Ipilimumab and nivolumab | Yttrium 90 | ORR: 20%; DCR: 68%; Median PFS: 5.5 months; Median OS: 15.0 months |
| Cavalieri et al. (99) | Immune checkpoint inhibitors | Carbon iON radiotherapy | The experiment is currently underway |
OS, overall survival; ORR, objective response rate; DCR, disease control rate; DRR, durable response rate; PFS, progression-free survival; HFRT, hypofractionated radiation therapy; SBRT, stereotactic body radiotherapy.